Olympus Adjusts Corporate Strategy Amid Directional Shift
TOKYO, Nov. 10, 2025 — Olympus Corporation has revealed a comprehensive strategy related to endoscopy-enabled care which seeks to accelerate technological development and reinforce the company’s leadership in the medical technology market.
According to Olympus CEO Bob White, the company is moving beyond hardware “toward a future defined by intelligent integrated care.
"By simplifying our organization, we are enhancing agility and making bold investments in the next generation of medical technology,” White said, in a press release.
Olympus plans to implement a global organizational transformation to align structure and resources with its strategic priorities of innovation-driven growth centered on AI-powered endoscopy, robotics, and cloud-connected solutions. The other two strategic pillars the company named are simplicity and accountability, which will serve as operational accelerators, streamline processes, and drive sustainable performance.
The company expects the planned changes to yield ~¥24 billion ($156 million) in run rate savings and a net reduction of roughly 2000 positions in the company’s global workforce. According to the company, the optimization will simplify organizational layers and expand managerial spans of control, fostering agility and clearer accountability.
Olympus is targeting 5% year-on-year revenue growth by FY 2029, among other growth points, with capital to be deployed to support innovation, dividends, share buybacks, and strategic mergers and acquisitions.
Leadership changes are also planned. Keith Boettiger, currently corporate officer and co-head of the Gastrointestinal Solutions Division, will be appointed executive officer and Gastrointestinal Solutions Division Head, effective April 1, 2026. He will succeed Frank Drewalowski, who will transition to senior advisor to the CEO, supporting Olympus’ strategic priorities.
Additionally, Yasuo Takeuchi will step down as representative executive officer, executive chairperson and ESG Officer at the end of March 2026, concluding more than 40 years of service. Takeuchi, who served as president and CEO beginning in 2019, led Olympus’ transformation into a pure-play medical technology company and cultivated its global purpose and core values.
/Buyers-Guide/Olympus-Corp/c33305